<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------
SCHEDULE 13E-3
(AMENDMENT NO. 1)
RULE 13E-3 TRANSACTION STATEMENT
(PURSUANT TO SECTION 13(E) OF THE SECURITIES EXCHANGE ACT OF 1934)
SYSTEMIX, INC.
(Name of the Issuer)
SYSTEMIX, INC.
NOVARTIS BIOTECH HOLDING CORP.
NOVARTIS INC.
(Name of Person(s) Filing Statement)
COMMON STOCK, PAR VALUE $.01 PER SHARE
(Title of Class of Securities)
871872-10-7
(CUSIP Number of Class of Securities)
<TABLE>
<S> <C>
ROBERT L. THOMPSON, JR., ESQ. IRIS BREST, ESQ.
NOVARTIS BIOTECH HOLDING CORP. SYSTEMIX, INC.
NOVARTIS INC. 3155 PORTER DRIVE
C/O NOVARTIS CORPORATION PALO ALTO, CALIFORNIA 94304
608 FIFTH AVENUE, 10TH FLOOR (415) 813-4119
NEW YORK, NEW YORK 10020
(212) 830-2401
</TABLE>
(Name, Address and Telephone Number of Persons Authorized to Receive Notices
and Communications on Behalf of Person(s) Filing Statement)
WITH COPIES TO:
<TABLE>
<S> <C>
DAVID W. HELENIAK, ESQ. MORRIS J. KRAMER, ESQ.
SHEARMAN & STERLING SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
599 LEXINGTON AVENUE 919 THIRD AVENUE
NEW YORK, NEW YORK 10022 NEW YORK, NEW YORK 10022
(212) 848-4000 (212) 735-3000
</TABLE>
This statement is filed in connection with (check the appropriate box):
a. / / The filing of solicitation materials or an information statement
subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under
the Securities Exchange Act of 1934.
b. / / The filing of a registration statement under the Securities Act
of 1933.
c. /X/ A tender offer.
d. / / None of the above.
Check the following box if the soliciting materials or information statement
referred to in checking box (a) are preliminary copies: [ ]
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
This Amendment No. 1 to the Rule 13e-3 Transaction Statement on
Schedule 13E-3 (this "Amendment") relates to the offer by Novartis Biotech
Holding Corp., a Delaware corporation ("Purchaser") and an indirect wholly
owned subsidiary of Novartis Inc., a company organized under the laws of
Switzerland ("Parent"), to purchase all outstanding shares of Common Stock,
par value $.01 per share (the "Common Stock"), of SyStemix, Inc. (the
"Shares"), a Delaware corporation, at a price of $19.50 per Share, net to
the seller in cash, upon the terms and subject to the conditions set forth
in Purchaser's Offer to Purchase dated January 17, 1997 and in the related
Letter of Transmittal.
ITEM 16. Additional Information.
Item 16 is hereby amended and supplemented as follows:
Parent and the other defendants have reached an agreement with
the plaintiffs to settle the consolidated action captioned In Re SyStemix, Inc.
Shareholder Litigation, Consolidated C.A. 15014. If this agreement is accepted
and approved by the Delaware Chancery Court, the case would be dismissed with
prejudice. As a part of such a settlement and dismissal, Parent and the other
defendants would not object to a court award of attorneys' fees and expenses
to counsel for plaintiffs of $385,000 or less.
<PAGE>
SIGNATURES
After due inquiry and to the best of its knowledge and belief, each of the
undersigned certifies that the information set forth in this statement is true,
complete and correct.
Dated: January 30, 1997 NOVARTIS BIOTECH HOLDING CORP.
By /s/ Robert L. Thompson, Jr.
-----------------------------------------
Name: Robert L. Thompson, Jr.
Title: Vice President
NOVARTIS INC.
By /s/ Robert L. Thompson, Jr.
-----------------------------------------
Name: Robert L. Thompson, Jr.
Title: Attorney-in-Fact
<PAGE>
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that
the information set forth in this statement is true, complete and correct.
Dated: January 30, 1997 SYSTEMIX, INC.
By /s/ John J. Schwartz
-----------------------------------------
Name: John J. Schwartz, Ph.D.
Title: President and Chief Executive
Officer
